BioSpace News Archive

DJO, LLC (“DJO” or the “Company”), a leading global provider of medical technologies to get and keep people moving, today announced the launch of the canal-sparing AltiVate® Anatomic CS EDGE™ Shoulder System. As the latest innovation from shoulder industry leader DJO®, the new system is designed to provide a more bone-sparing so

AngelMed is pleased to announce that on Tuesday, September 29th, a former ALERTS Study patient in the United States received the first implant of the next-generation AngelMed Guardian® System as part of the ALERTS-Continued Access Study.

Qualtrics, the leader in customer experience and creator of the experience management category, today announced that Netsmart Technologies, a company that designs, builds, and delivers electronic health records (EHRs), has selected Qualtrics CoreXM.

Praetego Inc (https://www.praetego.com/), a preclinical stage pharmaceutical company committed to improving health outcomes for patients living with diabetes, is pleased to announce the approval of a 3 year $2.1M STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP.TO)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, announced today that it has entered into a definitive agreement with a USA strategic partner to acquire the Canadian exclusive rights for Dronabinol Soft Gel capsules.

The 2nd Annual HealthTech Summit, hosted by IntuitiveX, is a rare opportunity for life science entrepreneurs and startups to gain insider information on how to successfully take their company to the next level without losing momentum.

Red Nucleus (“RN”), a premier provider of learning, performance, and process solutions for the life sciences industry, announced that it has acquired INVIVO Communications (“INVIVO”), a leading digital scientific communications agency.

The wearable sensor industry will be worth $2.5 billion in 2020, having tripled in size since 2014.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that updated top-line results from the Company’s Phase III trial, DESTINY PWS (C601),

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today is announcing that the Company’s M400 Smart Glasses are being used by University Malaya Specialist Centre (USMC) in Malaysia